Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from …
RK Hills, S Castaigne, FR Appelbaum… - The lancet …, 2014 - thelancet.com
Background Gemtuzumab ozogamicin was the first example of antibody-directed
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …
[HTML][HTML] Gemtuzumab Ozogamicin (GO) inclusion to induction chemotherapy eliminates leukemic initiating cells and significantly improves survival in mouse models of …
CC Zhang, Z Yan, B Pascual, A Jackson-Fisher… - Neoplasia, 2018 - Elsevier
Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-drug conjugate for the treatment of
acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early …
acute myeloid leukemia (AML). Although GO shows a narrow therapeutic window in early …
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
New developments in antibody therapy for acute myeloid leukemia
MR Tomblyn, MS Tallman - Seminars in oncology, 2003 - Elsevier
In the past three decades, improvements in the treatment of acute myeloid leukemia (AML)
have increased survival in patients younger than 55 years without significant survival impact …
have increased survival in patients younger than 55 years without significant survival impact …
A prognostic model for survival after salvage treatment with FLAG‐Ida+/− gemtuzumab‐ozogamicine in adult patients with refractory/relapsed acute myeloid …
JM Bergua, P Montesinos… - British Journal of …, 2016 - Wiley Online Library
The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony‐stimulating
factor (FLAG‐Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We …
factor (FLAG‐Ida) is widely used in relapsed/refractory acute myeloid leukaemia (AML). We …
Antibody therapy for acute myeloid leukemia
D Mulford - Seminars in hematology, 2008 - Elsevier
Due to the high rate of relapse in younger patients and the overall poor outcome in older
patients, novel therapies are needed for the treatment of acute myeloid leukemia (AML) …
patients, novel therapies are needed for the treatment of acute myeloid leukemia (AML) …
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse
EL Sievers - Expert opinion on biological therapy, 2001 - Taylor & Francis
Gemtuzumab ozogamicin (CMA-676, Mylotarg®), an antibody-targeted chemotherapy
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …
agent, was recently approved by the FDA for the treatment of patients with CD33+ acute …
Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg®) in acute myeloid leukemia
C Nabhan, MS Tallman - Clinical lymphoma, 2002 - Elsevier
Relapsed acute myeloid leukemia (AML) carries a poor prognosis. Treatment options are
limited, and their toxicities are substantial. There is an urgent need for novel therapies that …
limited, and their toxicities are substantial. There is an urgent need for novel therapies that …
Pharmacokinetics of gemtuzumab ozogamicin as a single‐agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia
M Buckwalter, JA Dowell… - The Journal of …, 2004 - Wiley Online Library
Gemtuzumab ozogamicin is currently approved to treat CD33‐positive acute myeloid
leukemia (AML) in first relapse in patients older than age 60 years. The objective of this …
leukemia (AML) in first relapse in patients older than age 60 years. The objective of this …
Pharmacokinetics of gemtuzumab ozogamicin, an antibody‐targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
JA Dowell, J Korth‐Bradley, H Liu… - The Journal of …, 2001 - Wiley Online Library
The purpose of this study was to characterize the pharmacokinetics of gemtuzumab
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …
ozogamicin (Mylotarg™; Wyeth‐Ayerst Laboratories, St. Davids, PA) in patients with acute …